MaxCyte, Inc. provided revenue guidance for the year 2022. The company expected core business revenue (instruments and disposables to cell therapy and drug discovery customers and excluding program-related revenue) in 2022 to grow approximately 30% compared to 2021. The company continue to expect SPL Program-related revenue to be approximately $4 million in 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
322 GBX | 0.00% | -0.92% | -8.65% |
06-11 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
06-11 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.65% | 426M | |
+3.77% | 210B | |
+8.83% | 186B | |
+31.94% | 158B | |
+33.19% | 113B | |
+5.25% | 66.13B | |
+22.41% | 56.25B | |
+1.34% | 49B | |
-5.92% | 38.16B | |
+1.94% | 35.98B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Year 2022